Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estrone Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | STS | P08842 | 9/20 | 0.90 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.90 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.73 |
| ▸ | CA2 | P00918 | 2/20 | 0.73 |
| ▸ | CA9 | Q16790 | 2/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone Sulfuric Acid SCHEMBL21577 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL481201 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL6556684 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL29366794 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL7216979 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL19100296 | 0.99 | CYP3A4 (0.98) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL6931138 | 0.99 | CYP3A4 (0.98) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL14844580 | 0.99 | CYP3A4 (0.98) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL23834600 | 0.96 | CYP3A4 (0.93) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL10772904 | 0.96 | CYP3A4 (0.93) | CYP3A4STSABCC4ABCC1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101896161-A | Solid formulations of crystalline compounds | PURDUE RESEARCH FOUNDATION | 2010-11-24 | — | — | CN | disclosed |
| US-20090005351-A1 | Hormone replacement therapy | WYETH | 2009-01-01 | — | — | US | disclosed |
| US-20080152699-A1 | Method of treating menopausal women transdermally with testosterone | THE PROCTER & GAMBLE COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080015170-A1 | Method of treating menopausal women transdermally with testosterone | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| EP-1857110-A2 | Hormone replacement therapy | Wyeth (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1769800-A2 | Estrogen replacement therapy | Wyeth a Corporation of the State of Delaware (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060142258-A1 | Estrogen replacement therapy | WYETH (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1265616-B1 | HORMONE REPLACEMENT THERAPY USING A COMBINATION OF CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE | WYETH CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1618882-A2 | Estrogen compositions for neuroprotection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| CN-1649595-A | Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy | WYETH CORP (US) | 2005-08-03 | — | — | CN | disclosed |
| WO-2003092699-A1 | USE OF CONJUGATED ESTROGENS IN COMBINATION WITH TRIMEGESTONE IN HORMONE REPLACEMENT THERAPY | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003084521-A2 | USE OF CONJUGATED ESTROGENS IN COMBINATION WITH TRIMEGESTONE IN HORMONE REPLACEMENT THERAPY | WYETH (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003084549-A1 | HORMONE REPLACEMENT THERAPY | WYETH, A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2002078682-A2 | ESTROGEN REPLACEMENT THERAPY | WYETH (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002074292-A2 | HORMONE REPLACEMENT THERAPY | WYETH (US) | 2002-09-26 | — | — | WO | disclosed |
| US-6455568-B2 | ADMINISTERING INDOLE DERIVATIVE DRUGS SUCH AS 2-(4-HYDROXY-PHENYL)-3-METHYL-1-(4-(2-PIPERIDIN-1-YL-ETHOXY)-BENZYL)-1H -INDOL-5-OL, AND ONE OR MORE ESTROGENS | WYETH | 2002-09-24 | — | — | US | disclosed |
| US-5843934-A | Uses of estrogen compounds for the treatment of disease | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0799041-A1 | ESTROGEN COMPOSITIONS AND METHOD FOR NEUROPROTECTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1995012402-A1 | ESTROGEN COMPOSITIONS AND METHOD FOR NEUROPROTECTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 1995-05-11 | — | — | WO | disclosed |
| US-4673667-A | THERAPY FOR DISEASES CAUSED BY BLOOD CLOTTING | TRUSTEES OF BOSTON UNIVERSITY (US) | 1987-06-16 | — | — | US | disclosed |